Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 14/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | TNKS | O95271 | 3/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31710757 | 1.00 | GUSB (0.76) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL18258699 | 0.93 | GUSB (0.78) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL18258692 | 0.89 | GUSB (0.59) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL2370223 | 0.89 | GUSB (0.59) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL29890298 | 0.89 | GUSB (0.59) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL11243512 | 0.86 | GUSB (0.70) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL31066914 | 0.86 | GUSB (1.00) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL16007727 | 0.86 | GUSB (1.00) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL31066916 | 0.86 | GUSB (1.00) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL296097 | 0.86 | GUSB (1.00) | GUSBKDM4EHPGDTNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170012218-A1 | NEAR-ULTRAVIOLET STIMULATED LIGHT-EMITTING COMPOUND AND PRODUCTION METHOD FOR SAME | NANO CMS CO., LTD. (KR) | 2017-01-12 | — | — | US | disclosed |
| US-20170012218-A1 | NEAR-ULTRAVIOLET STIMULATED LIGHT-EMITTING COMPOUND AND PRODUCTION METHOD FOR SAME | NANO CMS CO., LTD. (KR) | 2017-01-12 | — | — | US | disclosed |
| US-20170012218-A1 | NEAR-ULTRAVIOLET STIMULATED LIGHT-EMITTING COMPOUND AND PRODUCTION METHOD FOR SAME | NANO CMS CO., LTD. (KR) | 2017-01-12 | — | — | US | disclosed |
| EP-3098284-A1 | NEAR-ULTRAVIOLET STIMULATED LIGHT-EMITTING COMPOUND AND PRODUCTION METHOD FOR SAME | Nano CMS Co., Ltd. (KR) | 2016-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170012218-A1 | NEAR-ULTRAVIOLET STIMULATED LIGHT-EMITTING COMPOUND AND PRODUCTION METHOD FOR SAME | SUN2, TYR, SQLE | GUSB 1639/4885KDM4E 1890/4885HPGD 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.